Scholar Rock Holding (SRRK) Stock
Clinical stage biotech developing targeted disease treatments. Here's the price, business snapshot, and what's worth knowing about Scholar Rock Holding in June 2026.
Scholar Rock Holding Corp (SRRK) is a clinical‑stage biopharmaceutical company focused on developing therapies that modulate the transforming growth factor‑beta (TGF‑β) signalling pathway. The company’s pipeline targets conditions where TGF‑β is implicated, with several clinical programmes progressing through trials. As a specialist biotech, Scholar Rock’s value is shaped heavily by clinical results, regulatory decisions and partnerships rather than current product revenues. With a market capitalisation around $2.7 billion, the stock can offer exposure to potential upside from successful trials but also carries typical biotech risks: trial setbacks, regulatory hurdles and cash burn needing future financing. Investors should consider time horizon, risk tolerance and the binary nature of clinical catalysts. This summary is for educational purposes only and is not personalised investment advice; investors should conduct further research or consult an authorised financial adviser before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Scholar Rock's stock, as it is expected to perform better than its current price.
Financial Health
Scholar Rock is showing strong cash flow and book value, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring SRRK
Gene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: 25 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage drug focus
The company’s value hinges on clinical readouts and scientific validation, which can create material share‑price moves; outcomes are uncertain.
Pipeline catalysts ahead
Upcoming trial milestones and partnerships can drive momentum, though any positive prospects may be offset by trial or regulatory disappointment.
Regulatory and cashflow
Regulatory approvals and financing decisions will shape long‑term prospects; investors should watch cash runway and funding plans carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.